Druggability assessment of allosteric proteins by dynamics simulations in the presence of probe molecules

Journal of Chemical Theory and Computation

Volumn 8, Issue 7, 2012, Pages 2435-2447

  Bakan, Ahmet ^a   Nevins, Neysa ^b   Lakdawala, Ami S ^b   Bahar, Ivet ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863661333     PISSN: 15499618     EISSN: 15499626     Source Type: Journal    
DOI: 10.1021/ct300117j     Document Type: Article

References (84)

1. Hopkins, A. L.; Groom, C. R. The druggable genome Nat. Rev. Drug Discovery 2002, 1, 727-730
2. Brown, D.; Superti-Furga, G. Rediscovering the sweet spot in drug discovery Drug Discovery Today 2003, 8, 1067-1077
3. Keller, T. H.; Pichota, A.; Yin, Z. A practical view of druggability Curr. Opin. Chem. Biol. 2006, 10, 357-361
4. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48, 2518-2525
5. Allen, K. N.; Bellamacina, C. R.; Ding, X.; Jeffery, C. J.; Mattos, C.; Petsko, G. A.; Ringe, D. An Experimental Approach to Mapping the Binding Surfaces of Crystalline Proteins J. Phys. Chem. 1996, 100, 2605-2611
6. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, A. C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecule druggability Nat. Biotechnol. 2007, 25, 71-75
7. Halgren, T. A. Identifying and characterizing binding sites and assessing druggability J. Chem. Inf. Model. 2009, 49, 377-389
8. Schmidtke, P.; Barril, X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites J. Med. Chem. 2010, 53, 5858-5867
9. Huang, N.; Jacobson, M. P. Binding-site assessment by virtual fragment screening PLoS One 2010, 5, e10109
10. Brenke, R.; Kozakov, D.; Chuang, G. Y.; Beglov, D.; Hall, D.; Landon, M. R.; Mattos, C.; Vajda, S. Fragment-based identification of druggable hot spots of proteins using Fourier domain correlation techniques Bioinformatics 2009, 25, 621-627
11. Ngan, C.; Hall, D. R.; Zerbe, B.; Grove, L. E.; Kozakov, D.; Vajda, S. FTSite: High accuracy detection of ligand binding sites on unbound protein structures Bioinformatics 2012, 28, 286-287
12. Brown, S. P.; Hajduk, P. J. Effects of conformational dynamics on predicted protein druggability ChemMedChem. 2006, 1, 70-72
13. Ivetac, A.; McCammon, J. A. Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach Chem. Biol. Drug Des. 2010, 76, 201-217
14. Carlson, H. A.; McCammon, J. A. Accommodating protein flexibility in computational drug design Mol. Pharmacol. 2000, 57, 213-218
15. Rueda, M.; Bottegoni, G.; Abagyan, R. Consistent improvement of cross-docking results using binding site ensembles generated with elastic network normal modes J Chem. Inf. Model. 2009, 49, 716-725
16. Cavasotto, C. N.; Abagyan, R. A. Protein flexibility in ligand docking and virtual screening to protein kinases J. Mol. Biol. 2004, 337, 209-225
17. Floquet, N.; Marechal, J. D.; Badet-Denisot, M. A.; Robert, C. H.; Dauchez, M.; Perahia, D. Normal mode analysis as a prerequisite for drug design: application to matrix metalloproteinases inhibitors FEBS Lett. 2006, 580, 5130-5136
18. May, A.; Zacharias, M. Protein-ligand docking accounting for receptor side chain and global flexibility in normal modes: evaluation on kinase inhibitor cross docking J. Med. Chem. 2008, 51, 3499-3506
19. Bahar, I.; Lezon, T. R.; Bakan, A.; Shrivastava, I. H. Normal mode analysis of biomolecular structures: functional mechanisms of membrane proteins Chem. Rev. 2010, 110, 1463-1497
20. Bakan, A.; Bahar, I. The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding Proc. Natl. Acad. Sci. U. S. A 2009, 106, 14349-14354
21. Meireles, L. M.; Gur, M.; Bakan, A.; Bahar, I. Pre-existing Soft Modes of Motion Uniquely Defined by Native Contact Topology Facilitate Ligand Binding to Proteins. Protein Sci. 2011, not supplied
22. Lexa, K. W.; Carlson, H. A. Full Protein Flexibility Is Essential for Proper Hot-Spot Mapping J. Am. Chem. Soc. 2010, 133, 200-202
23. Hall, D. H.; Grove, L. E.; Yueh, C.; Ngan, C. H.; Kozakov, D.; Vajda, S. Robust identification of binding hot spots using continuum electrostatics: application to hen egg-white lysozyme J. Am. Chem. Soc. 2011, 133, 20668-20671
24. Kulp, J. L., III; Kulp, J. L., Jr.; Pompliano, D. L.; Guarnieri, F. Diverse fragment clustering and water exclusion identify protein hot spots J. Am. Chem. Soc. 2011, 133, 10740-10743
25. Guvench, O.; Mackerell, A. D., Jr. Computational fragment-based binding site identification by ligand competitive saturation PLoS Comput. Biol. 2009, 5, e1000435
26. Raman, E. P.; Yu, W.; Guvench, O.; Mackerell, A. D. Reproducing crystal binding modes of ligand functional groups using Site-Identification by Ligand Competitive Saturation (SILCS) simulations J. Chem. Inf. Model. 2011, 51, 877-896
27. Seco, J.; Luque, F. J.; Barril, X. Binding site detection and druggability index from first principles J. Med. Chem. 2009, 52, 2363-2371
28. Mattos, C.; Ringe, D. Locating and characterizing binding sites on proteins Nat. Biotechnol. 1996, 14, 595-599
29. Liepinsh, E.; Otting, G. Organic solvents identify specific ligand binding sites on protein surfaces Nat. Biotechnol. 1997, 15, 264-268
30. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: a comprehensive resource for omics research on drugs Nucleic Acids Res. 2011, 39, D1035-D1041
31. Kirtay, C. K.; Mitchell, J. B. O.; Lumley, J. A. Knowledge Based Potentials: the Reverse Boltzmann Methodology, Virtual Screening and Molecular Weight Dependence. QSAR Comb. Sci. 205, 24
32. Thomas, P. D.; Dill, K. A. Statistical potentials extracted from protein structures: how accurate are they? J. Mol. Biol. 1996, 257, 457-469
33. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53 Nature 1997, 387, 296-299
34. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy Nat. Rev. Cancer 2003, 3, 102-109
35. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 1996, 274, 948-953
36. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004, 303, 844-848
37. Zhong, H.; Carlson, H. A. Computational studies and peptidomimetic design for the human p53-MDM2 complex Proteins 2005, 58, 222-234
38. Yu, S.; Qin, D.; Shangary, S.; Chen, J.; Wang, G.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S.; Yang, D.; Wang, S. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2009, 52, 7970-7973
39. Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A. D., Jr. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields J. Comput. Chem. 2010, 31, 671-690
40. Uhrinova, S.; Uhrin, D.; Powers, H.; Watt, K.; Zheleva, D.; Fischer, P.; McInnes, C.; Barlow, P. N. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding J. Mol. Biol. 2005, 350, 587-598
41. Xin, Z.; Liu, G.; Abad-Zapatero, C.; Pei, Z.; Szczepankiewicz, B. G.; Li, X.; Zhang, T.; Hutchins, C. W.; Hajduk, P. J.; Ballaron, S. J.; Stashko, M. A.; Lubben, T. H.; Trevillyan, J. M.; Jirousek, M. R. Identification of a monoacid-based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B Bioorg. Med. Chem. Lett. 2003, 13, 3947-3950
42. Puius, Y. A.; Zhao, Y.; Sullivan, M.; Lawrence, D. S.; Almo, S. C.; Zhang, Z. Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 13420-13425
43. Wiesmann, C.; Barr, K. J.; Kung, J.; Zhu, J.; Erlanson, D. A.; Shen, W.; Fahr, B. J.; Zhong, M.; Taylor, L.; Randal, M.; McDowell, R. S.; Hansen, S. K. Allosteric inhibition of protein tyrosine phosphatase 1B Nat. Struct Mol. Biol. 2004, 11, 730-737
44. Li, S.; Depetris, R. S.; Barford, D.; Chernoff, J.; Hubbard, S. R. Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase Structure 2005, 13, 1643-1651
45. Marlin, S. D.; Springer, T. A. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) Cell 1987, 51, 813-819
46. Qu, A.; Leahy, D. J. The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin Structure 1996, 4, 931-942
47. Crump, M. P.; Ceska, T. A.; Spyracopoulos, L.; Henry, A.; Archibald, S. C.; Alexander, R.; Taylor, R. J.; Findlow, S. C.; OConnell, J.; Robinson, M. K.; Shock, A. Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry Biochemistry 2004, 43, 2394-2404
48. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 2007, 35, D198-D201
49. Guckian, K. M.; Lin, E. Y.; Silvian, L.; Friedman, J. E.; Chin, D.; Scott, D. M. Design and synthesis of a series of meta aniline-based LFA-1 ICAM inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 5249-5251
50. Yan, Y.; Sardana, V.; Xu, B.; Homnick, C.; Halczenko, W.; Buser, C. A.; Schaber, M.; Hartman, G. D.; Huber, H. E.; Kuo, L. C. Inhibition of a mitotic motor protein: where, how, and conformational consequences J. Mol. Biol. 2004, 335, 547-554
51. Roecker, A. J.; Coleman, P. J.; Mercer, S. P.; Schreier, J. D.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Lobell, R. B.; Tao, W.; Diehl, R. E.; South, V. J.; Davide, J. P.; Kohl, N. E.; Yan, Y.; Kuo, L. C.; Li, C.; Fernandez-Metzler, C.; Mahan, E. A.; Prueksaritanont, T.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5- dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP Bioorg. Med. Chem. Lett. 2007, 17, 5677-5682
52. Kim, K. S.; Lu, S.; Cornelius, L. A.; Lombardo, L. J.; Borzilleri, R. M.; Schroeder, G. M.; Sheng, C.; Rovnyak, G.; Crews, D.; Schmidt, R. J.; Williams, D. K.; Bhide, R. S.; Traeger, S. C.; McDonnell, P. A.; Mueller, L.; Sheriff, S.; Newitt, J. A.; Pudzianowski, A. T.; Yang, Z.; Wild, R.; Lee, F. Y.; Batorsky, R.; Ryder, J. S.; Ortega-Nanos, M.; Shen, H.; Gottardis, M.; Roussell, D. L. Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 3937-3942
53. Sindelar, C. V.; Downing, K. H. The beginning of kinesins force-generating cycle visualized at 9-A resolution J. Cell Biol. 2007, 177, 377-385
54. Bodey, A. J.; Kikkawa, M.; Moores, C. A. 9-Angstrom structure of a microtubule-bound mitotic motor J. Mol. Biol. 2009, 388, 218-224
55. Luo, L.; Parrish, C. A.; Nevins, N.; McNulty, D. E.; Chaudhari, A. M.; Carson, J. D.; Sudakin, V.; Shaw, A. N.; Lehr, R.; Zhao, H.; Sweitzer, S.; Lad, L.; Wood, K. W.; Sakowicz, R.; Annan, R. S.; Huang, P. S.; Jackson, J. R.; Dhanak, D.; Copeland, R. A.; Auger, K. R. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism Nat. Chem. Biol. 2007, 3, 722-726
56. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases Nat. Rev. Drug Discovery 2003, 2, 717-726
57. Pettus, L. H.; Wurz, R. P.; Xu, S.; Herberich, B.; Henkle, B.; Liu, Q.; McBride, H. J.; Mu, S.; Plant, M. H.; Saris, C. J.; Sherman, L.; Wong, L. M.; Chmait, S.; Lee, M. R.; Mohr, C.; Hsieh, F.; Tasker, A. S. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase J. Med. Chem. 2010, 53, 2973-2985
58. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat. Struct. Biol. 2002, 9, 268-272
59. White, A.; Pargellis, C. A.; Studts, J. M.; Werneburg, B. G.; Farmer, B. T. Molecular basis of MAPK-activated protein kinase 2:p38 assembly Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 6353-6358
60. ter Haar, E.; Prabhakar, P.; Liu, X.; Lepre, C. Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer J. Biol. Chem. 2007, 282, 9733-9739
61. Diskin, R.; Engelberg, D.; Livnah, O. A novel lipid binding site formed by the MAP kinase insert in p38á J. Mol. Biol. 2008, 375, 70-79
62. Perry, J. J.; Harris, R. M.; Moiani, D.; Olson, A. J.; Tainer, J. A. p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses J. Mol. Biol. 2009, 391, 1-11
63. Turner, J.; Anderson, R.; Guo, J.; Beraud, C.; Fletterick, R.; Sakowicz, R. Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker J. Biol. Chem. 2001, 276, 25496-25502
64. Bakan, A.; Bahar, I. Computational Generation of Inhibitor-Bound Conformers of p38 MAP Kinase and Comparison with Experiments Pac. Symp. Biocomput. 2011 2011, 16, 181-192
65. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
66. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 9997-10002
67. Böhm, H. J.; Klebe, G. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew. Chem., Int. Ed. Engl. 1996, 35, 2588-2614
68. Clackson, T.; Wells, J. A. A hot spot of binding energy in a hormone-receptor interface Science 1995, 267, 383-386
69. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions J. Med. Chem. 2006, 49, 5912-5931
70. English, A. C.; Groom, C. R.; Hubbard, R. E. Experimental and computational mapping of the binding surface of a crystalline protein Protein Eng. 2001, 14, 47-59
71. Chang, C. E.; Chen, W.; Gilson, M. K. Ligand configurational entropy and protein binding Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 1534-1539
72. Mobley, D. L.; Graves, A. P.; Chodera, J. D.; McReynolds, A. C.; Shoichet, B. K.; Dill, K. A. Predicting absolute ligand binding free energies to a simple model site J. Mol. Biol. 2007, 371, 1118-1134
73. Boyce, S. E.; Mobley, D. L.; Rocklin, G. J.; Graves, A. P.; Dill, K. A.; Shoichet, B. K. Predicting ligand binding affinity with alchemical free energy methods in a polar model binding site J. Mol. Biol. 2009, 394, 747-763
74. Leeson, P. D.; St-Gallay, S. A.; Wenlock, M. C. Impact of ion class and time on oral drug molecular properties Med. Chem. Commun. 2011, 2, 91-105
75. Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD J. Comput. Chem. 2005, 26, 1781-1802
76. Brooks, B. R.; Brooks, C. L., III; Mackerell, A. D., Jr.; Nilsson, L.; Petrella, R. J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. M.; Karplus, M. CHARMM: the biomolecular simulation program J. Comput. Chem. 2009, 30, 1545-1614
77. Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics J. Mol. Graphics 1996, 14, 33-38
78. Bakan, A.; Meireles, L. M.; Bahar, I. ProDy: Protein Dynamics Inferred from Theory and Experiments. Bioinformatics. 2011, not supplied
79. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
80. Liu, G.; Xin, Z.; Liang, H.; bad-Zapatero, C.; Hajduk, P. J.; Janowick, D. A.; Szczepankiewicz, B. G.; Pei, Z.; Hutchins, C. W.; Ballaron, S. J.; Stashko, M. A.; Lubben, T. H.; Berg, C. E.; Rondinone, C. M.; Trevillyan, J. M.; Jirousek, M. R. Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands J. Med. Chem. 2003, 46, 3437-3440
81. Wang, Z.; Harkins, P. C.; Ulevitch, R. J.; Han, J.; Cobb, M. H.; Goldsmith, E. J. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 2327-2332
82. Wrobleski, S. T.; Lin, S.; Hynes, J., Jr.; Wu, H.; Pitt, S.; Shen, D. R.; Zhang, R.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W.; Doweyko, A. M.; Kish, K. F.; Tredup, J. A.; Duke, G. J.; Sack, J. S.; McKinnon, M.; Dodd, J.; Barrish, J. C.; Schieven, G. L.; Leftheris, K. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 2739-2744
83. Yu, S.; Qin, D.; Shangary, S.; Chen, J.; Wang, G.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S.; Yang, D.; Wang, S. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2009, 52, 7970-7973
84. Yu, S.; Qin, D.; Shangary, S.; Chen, J.; Wang, G.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S.; Yang, D.; Wang, S. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2009, 52, 7970-7973